STUB1 and myeloid neoplasm: CHIP will also be included as an entity in the 5th edition of the World Health Organization Classification of Hematolymphoid Tumors where it will be defined similarly by the presence of somatic mutations of myeloid malignancy-associated genes detected in the blood or bone marrow with a VAF ≥ 2% (≥4% for X-linked gene mutations in males) in individuals without a diagnosed hematologic disorder or unexplained cytopenia [12].